<DOC>
	<DOCNO>NCT00779883</DOCNO>
	<brief_summary>The study Phase I , dose-escalating , non-randomized , single institution clinical trial assess safety efficacy autologous Ad-ISF35-transduced CLL B cell administer single intravenous infusion patient chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>A Phase I Trial Autologous CLL B Cells Transduced Express Chimeric CD154 ( ISF35 )</brief_title>
	<detailed_description>Memgen 's first TNF family derive product , ISF35 , gene encodes recombinant protein molecule bind activate human CD40+ B lymphocytes find vast majority malignant leukemias lymphoma . In clinical trial , ISF35 introduce patient ' CLL cell ex vivo use replication-defective adenovirus Ad5 encode ISF35 cDNA transgene . After ex vivo manipulation , modify leukemia cell extensively wash amount remain free virus measure cell reinfused patient . Following ex vivo transduction , CLL cell express ISF35 activate therapeutic immune response direct target leukemia cell . This ascending-dose trial divide three dose cohort determine existence maximum tolerate dose . Patients follow 12 month ISF35 administration initiation another treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Subjects must diagnosis B cell CLL , measurable disease , NCIWG indication treatment one following : Massive ( &gt; 6 cm leave costal margin ) progressive splenomegaly ; Massive ( &gt; 10 cm long diameter ) lymph node , nodal cluster , progressive lymphadenopathy ; Progressive anemia ; Progressive thrombocytopenia ; Weight loss &gt; 10 % body weight precede 6 month period ; Fatigue attributable CLL ; Fever night sweat without evidence infection ; Progressive lymphocytosis . 2 . Subjects must age 18 year old . 3 . Women childbearing potential ( postmenopausal least one year surgically incapable bear child ) must agree become pregnant duration study . Both men woman participant must agree use contraception duration study . 4 . Subjects must Zubrod performance status ≤ 2 ( Appendix B ) . 5 . Subjects must adequate hematologic , renal , hepatic , coagulation function : Adequate hematologic function : Platelet count ≥ 50,000/μl ; AND Hemoglobin ≥ 10 g/dl ( may support erythropoietin transfusion ) . Adequate renal function : Serum creatinine ≤ 1.5 time upper limit normal ; OR Measured creatinine clearance ≥ 40 mL/min/1.73 m^2 . Adequate hepatic function : Total bilirubin ≤ 2.5 time upper limit normal ; AND ALT ≤ 2.5 time upper limit normal ; AND Adequate coagulation test : Prothrombin time international normalize ratio ( INR ) ≤ 2 ; AND Partial thromboplastin time ≤ 1.66 time upper limit normal 6 . Subjects must able give write informed consent . 1 . Presence 55 % prolymphocytes . 2 . Chemotherapy ( e.g. , purine analogue , alkylating agent , corticosteroid ) , antibody therapy , immunotherapy , radiation therapy , participation investigational drug treatment within 4 week enrollment protocol time study . 3 . Ongoing toxicity prior antineoplastic therapy . 4 . Prior gene therapy allogeneic stem cell transplantation . 5 . Untreated autoimmune hemolytic anemia immune thrombocytopenia . 6 . Active infection require parenteral antibiotic . 7 . Known HIV/HBV/HCV seropositivity . 8 . Uncompensated hypothyroidism ( define TSH great 4x upper limit normal treated replacement hormone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>ISF35</keyword>
	<keyword>Ad-ISF35</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Immune therapy</keyword>
	<keyword>Active immune therapy</keyword>
</DOC>